000284032 001__ 284032
000284032 005__ 20260119111814.0
000284032 0247_ $$2doi$$a10.1007/s00115-025-01839-1
000284032 0247_ $$2pmid$$apmid:40548968
000284032 0247_ $$2ISSN$$a0028-2804
000284032 0247_ $$2ISSN$$a1433-0407
000284032 037__ $$aDZNE-2026-00075
000284032 041__ $$aGerman
000284032 082__ $$a610
000284032 1001_ $$0P:(DE-2719)2811675$$aMüller, Daniel J$$b0
000284032 245__ $$aGenetisch informierte Therapie in der Psychiatrie: neue Dynamik durch APOE und Antikörpertherapie der Alzheimer-Krankheit | Genetically informed treatment in psychiatry: new dynamics through APOE and antibody treatment of Alzheimer's disease
000284032 260__ $$aHeidelberg$$bSpringer$$c2026
000284032 3367_ $$2DRIVER$$aarticle
000284032 3367_ $$2DataCite$$aOutput Types/Journal article
000284032 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1768817783_6719$$xReview Article
000284032 3367_ $$2BibTeX$$aARTICLE
000284032 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284032 3367_ $$00$$2EndNote$$aJournal Article
000284032 520__ $$aThe European Medicines Agency has recommended testing for the ApoE-genotype prior to treatment of Alzheimer's disease with Lecanemab. The drug approval is limited to patients who are not homozygous for the ApoE epsilon 4 allele. This is to reduce the risk of undesired adverse effects in the patients treated with Lecanemab. With this recommendation for the first time a psychiatric therapy will be genetically informed.
000284032 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000284032 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000284032 650_7 $$2Other$$aApoE-genotype
000284032 650_7 $$2Other$$aAdverse effects
000284032 650_7 $$2Other$$aAlzheimer disease
000284032 650_7 $$2Other$$aLecanemab
000284032 650_7 $$2Other$$aMedication safety
000284032 650_7 $$2NLM Chemicals$$aAntibodies, Monoclonal, Humanized
000284032 650_7 $$2NLM Chemicals$$aApolipoproteins E
000284032 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000284032 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000284032 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000284032 650_2 $$2MeSH$$aHumans
000284032 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: therapeutic use
000284032 650_2 $$2MeSH$$aAntibodies, Monoclonal, Humanized: adverse effects
000284032 650_2 $$2MeSH$$aGenetic Testing: methods
000284032 650_2 $$2MeSH$$aGenetic Predisposition to Disease: genetics
000284032 650_2 $$2MeSH$$aApolipoproteins E: genetics
000284032 7001_ $$aFreitag, Christine M$$b1
000284032 7001_ $$aHeilbronner, Urs$$b2
000284032 7001_ $$0P:(DE-2719)9000400$$aNöthen, Markus M$$b3
000284032 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b4$$udzne
000284032 7001_ $$aRietschel, Marcella$$b5
000284032 7001_ $$aSchulte, Eva C$$b6
000284032 7001_ $$aDeckert, Jürgen$$b7
000284032 7001_ $$aReferat Genetische, molekulare und zelluläre Neurowissenschaften der DGPPN$$b8$$eCollaboration Author
000284032 773__ $$0PERI:(DE-600)1462945-8$$a10.1007/s00115-025-01839-1$$gVol. 97, no. 1, p. 82 - 85$$n1$$p82 - 85$$tDer Nervenarzt$$v97$$x0028-2804$$y2026
000284032 8564_ $$uhttps://pub.dzne.de/record/284032/files/DZNE-2026-00075_Restricted.pdf
000284032 8564_ $$uhttps://pub.dzne.de/record/284032/files/DZNE-2026-00075_Restricted.pdf?subformat=pdfa$$xpdfa
000284032 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000284032 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000284032 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000284032 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-07$$wger
000284032 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNERVENARZT : 2022$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000284032 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000284032 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x0
000284032 980__ $$ajournal
000284032 980__ $$aEDITORS
000284032 980__ $$aVDBINPRINT
000284032 980__ $$aI:(DE-2719)5000022
000284032 980__ $$aUNRESTRICTED